Download PDF
Hamostaseologie 1996; 16(02): 151-163
DOI: 10.1055/s-0038-1656650
Übersichtsarbeiten/Review Articles
Schattauer GmbH

Megakaryocytes and Platelets as the Main Cause for Vascular Events in Chronic Myeloproliferative Disorders

A. Wehmeier
1   Klinik für Hämatologie, Onkologie und klinische Immunologie, Heinrich-Heine-Universität Düsseldorf
,
W. Schneider
1   Klinik für Hämatologie, Onkologie und klinische Immunologie, Heinrich-Heine-Universität Düsseldorf
› Author Affiliations
Further Information

Publication History

Publication Date:
23 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Megakaryocytes are part of clonal hematopoiesis in chronic myeloproliferative disorders and are responsible for most of the clinical complications in this disease. About 30-40% of patients with polycythemia vera (PV) and essential thrombocythemia (ET) suffer from thrombotic complications, and microcirculatory disorders are common. Spontaneous bleeding mainly from the gastrointestinal tract is another complication that is especially prevalent in myelofibrosis and advanced stages of chronic myeloid leukemia.

In vivo, the bone marrow is hypercellular and the concentration of megakaryocytes increased with characteristic morphological abnormalities. Megakaryocytes are enlarged and ploidy is increased in PV and ET but small mononuclear cells with decreased ploidy are a feature of CML. Despite spontaneous growth in cul-ture, megakaryocytes in chronic MPD are hypersensitive to added interleukin-3, interleukin-6 and GM-CSF.

Platelets released from these megakaryocytes show abnormal morphology and ultrastructure, reflected in loss of storage granules and organelles, increased volume distribution and low buoyant density. Uptake, storage and secretion of platelet dense granule constituents is abnormal, and the plasma levels of platelet specific proteins which may also include growth factors for fibroblasts are elevated. At high platelet counts, spontaneous aggregation is observed, whereas agonist-induced aggregation in vitro with adrenaline, ADP and collagen is often defective. Platelet thromboxane generation may be stimulated, and production along the lipoxygenase pathway is decreased. Abnormalities of glycoprotein receptors and decreased fibrinogen binding have been reported but their clinical significance is uncertain. Several observations suggest that not only receptor defects but ineffective intracellular signalling may be responsible for platelet function abnormalities.

No single underlying defect has been discovered that could explain this variety of pathological findings. Moreover, a combination of intrinsic megakaryocyte abnormalities and increased susceptibility of platelets to activation makes it difficult to differentiate secondary phenomena from effects of clonal hematopoiesis. How-ever, there are some clinical guidelines for therapy.

Most elderly patients will be treated with cytoreductive therapy. Alkylating drugs and 32P have been shown to be leukemogenic, but even hydroxyurea may have a 10% incidence of leukemia induction after long-term therapy. Therapy with platelet-inhibitory drugs is often not sufficient to control thrombosis, and may aggravate a bleeding tendency, so that younger patients with PV and ET are increasingly treated with anagrelide or interferon alpha (A-IFN). Anagrelide is a quinazolin derivative that specifically inhibits megakaryocytopoiesis, while A-IFN may suppress clonal hematopoiesis by an unknown mechanism.

Keywords

Myeloproliferative disorders - megakaryocytes - platelets
 

  • REFERENCES

  • 1 Gunz FW. The epidemiology and genetics of the chronic leukemias. Clin Haematol 1977; 6: 3
    PubMedGoogle Scholar
  • 2 Modan B.. The epidemiology of polycythemia vera. In: Polycythemia vera and the myeloproliferative disorders. Wasserman LR, Berk PD, Berlin NI. (eds). Philadelphia: WB Saunders Company; 1995: 140-6
    Google Scholar
  • 3 Hand H, Laszlo J, Murphy S.. Essential thrombocythemia. In: Polycythemia vera and the myeloproliferative disorders. Wasserman LR, Berk PD, Berlin NI. (eds). Philadelphia: WB Saunders Company; 1995: 292-310
    Google Scholar
  • 4 Epstein E, Goedel A. Hämorrhagische Thrombocythämie bei vasculärer Schrumpfmilz. Virch Arch 1934; 292: 233-48
    CrossrefPubMedGoogle Scholar
  • 5 Gunz FW. Hemorrhagic thrombocythemia: a critical review. Blood 1960; 15: 706-23
    PubMedGoogle Scholar
  • 6 Swolin B, Weinfeld A, Westin J. A prospective longterm cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood 1988; 72: 386-95
    PubMedGoogle Scholar
  • 7 Pierre RV, Whang-Peng J. Cytogenetics. In:Polycythemia vera and the myeloproliferative disorders Wasserman LR, Berk PD, Berlin NI. 1995; 91-101
    PubMedGoogle Scholar
  • 8 Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975; 12: 339-51
    PubMedGoogle Scholar
  • 9 Murphy S, Hand H, Rosenthal D, Laszlo J. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin Hematol 1986; 23: 177-82
    PubMedGoogle Scholar
  • 10 Hoffman R, Boswell HS. Polycythemia vera. In: Hematology. Basic principles and practice. Hoffman R. R. J, Benz j, Shattil SJ, Furie B, Cohen HJ. (eds) New York: Churchill Livingstone Inc.; 1991: 834-54
    Google Scholar
  • 11 Buss DH, Cashell AW, O'Connor ML, Richards F, Case LD. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med 1994; 96: 247-53
    CrossrefPubMedGoogle Scholar
  • 12 Rolovic Z, Basara N, Gotic M, Sefer D, Bogdanovic A. The determination of spontaneous megakaryocyte colony formation is an unequivocal test for discrimination between essential thrombocythaemia and reactive thrombocytosis. Br J Haematol 1995; 90: 326-31
    CrossrefPubMedGoogle Scholar
  • 13 Rozman C, Giralt M, Feliu E, Rubio D, Cortés MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991; 67: 2658-63
    CrossrefPubMedGoogle Scholar
  • 14 Barbui T. Clinical epidemiology of thrombosis in 1213 patients with polycythemia vera (PV). Is a clinical trial of antithrombotic drugs feasible?. Blood 1994; 84 (Suppl. 01) 57a
    PubMedGoogle Scholar
  • 15 Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Polycythemia vera and the myeloproliferative disorders. Wasserman LR, Berk PD, Berlin NI. (eds). Philadelphia: WB Saunders Company; 1995: 166-94
    Google Scholar
  • 16 Griesshammer M, Scifried E, Heimpel H. Essentielle Thrombozythämie. Klinische Bedeutung, Diagnostik und Therapie. Dtsch Med Wochenschr 1993; 118 (39) 1412-7
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 van Genderen PJ, Michiels JJ. Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Presse Med 1994; 23: 73-7
    PubMedGoogle Scholar
  • 18 Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. Ann Hematol 1991; 63: 101-6
    CrossrefPubMedGoogle Scholar
  • 19 Muller EW, De Wolf JT, Haagsma EB. Portal hypertension as presenting feature of a myeloproliferative disorder. Diagnosis and therapeutic dilemmas. Scand J Gastroenterol 1993; 200: 74-9
    PubMedGoogle Scholar
  • 20 Najean Y, Dresch C, Rain JD. The verylong-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group. Br J Haematol 1994; 86: 233-5
    CrossrefPubMedGoogle Scholar
  • 21 Hehlmann H, Heimpel H, Hasford J. Randomized comparison of interferona, hydroxyurea, and busulfan in chronic myeloid leukemia: response to Kantarjian and Talpaz and to Tura and Baccarani. Blood 1995; 85: 3000-2
    PubMedGoogle Scholar
  • 22 Wehmeier A, Popescu A, Schneider W. Incidence of bleeding and thrombotic complications increase in advanced stages of chronic myeloid leukemia. A retrospective analysis of 182 patients. Ann Hematol 1996; 72 (Suppl. 01) A24
    PubMedGoogle Scholar
  • 23 Peterson P, Ellis JT. The bone marrow in polycythemia vera. In: Polycythemia vera and the myeloproliferative disorders. Wasserman LR, Berk PD, Berlin NI. (eds) Philadelphia: WB Saunders Company; 1995: 31-53
    Google Scholar
  • 24 Ellis JT, Peterson P. The bone marrow in polycythemia vera. Pathol Annu 1979; 14: 383-403
    PubMedGoogle Scholar
  • 25 Thiele J, Holgado S, Choritz H, Georgii A. Density distribution and size of megakaryocytes in inflammatory reactions of the bone marrow (myelitis) and chronic myeloproliferative diseases. Scand J Haematol 1983; 31: 329-41
    PubMedGoogle Scholar
  • 26 Thiele J, Schneider G, Hoeppner B, Wienholt S, Zankovich R, Fischer R.. Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosisfeatures of significance for the diagnosis of primary (essential) thrombocythaemia. Virchows Arch (A) 1988: 413-7
    Google Scholar
  • 27 Penington DG, Olsen TE. Megakaryocytes in states of altered platelet production: cell numbers, size, and DNA content. Br J Haematol 1970; 18: 447-63
    CrossrefPubMedGoogle Scholar
  • 28 Hancock V, Martin JF, Lelchuk R. The relationship between human megakaryocyte nuclear DNA content and gene expression. Br J Haematol 1993; 85: 692-7
    CrossrefPubMedGoogle Scholar
  • 29 Queißer W, Weidenauer G, Queißer U, Kempgens U, Müller U. Megakaryocyte polyploidization in myeloproliferative disorders. Blut 1976; 32: 13-20
    CrossrefPubMedGoogle Scholar
  • 30 Tomer A, Friese P, Conklin R. et al Flow cytometric analysis of megakaryocytes from patients with abnormal platelet counts. Blood 1989; 74: 594-601
    PubMedGoogle Scholar
  • 31 Woods MJ, Greaves M, Trowbridge EA. Megakaryocyte ploidy in thrombocytosis: improved microdensitometric measurements with a new image analysis system. Eur J Haematol 1990; 44: 220-6
    PubMedGoogle Scholar
  • 32 Kanz L, Hollen C, Friese P, Burstein SA. Analysis of megakaryocyte ploidy in patients with thrombocytosis. Int J Cell Cloning 1990; 8: 299-306
    CrossrefPubMedGoogle Scholar
  • 33 Rabellino EM, Levene RB, Nachman RL, Leung LLK. Human megakaryocytes III. Characterization in myeloproliferative disorders. Blood 1984; 63: 615-22
    PubMedGoogle Scholar
  • 34 Thiele J, Titius BR, Kvasnicka HM, Rechmeier W, Fischer R. Megakaryopoiesis in chronic myeloproliferative disorders: immunohistochemical evaluation of endoreduplicative activity by PCNA-staining reaction. Anal Cell Pathol 1994; 7: 63-75
    PubMedGoogle Scholar
  • 35 Souyri M, Vigon I, Penciolelli JF, Heard JM, Tambourin P, Wendling F. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 1990; 63: 1137-47
    CrossrefPubMedGoogle Scholar
  • 36 Methia N, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993; 82: 1395-401
    PubMedGoogle Scholar
  • 37 Chen J, Herceg-Harjacek L, Groopman JE, Grabarek J. Regulation of platelet activation in vitro by the c-mpl ligand, thrombopoietin. Blood 1995; 86: 4054-62
    PubMedGoogle Scholar
  • 38 Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 1995; 85: 1719-26
    PubMedGoogle Scholar
  • 39 Gewirtz AM, Hoffman R. Human megakaryocyte production: cell biology and clinical considerations. Hematol Oncol Clin North Am 1990; 4: 43-64
    CrossrefPubMedGoogle Scholar
  • 40 Bouscary D, Prudhomme C, Quesnel B, Melle J, Picard F, Dreyfus F. c-mpl expression in hematologic disorders. Leuk Lymphoma 1995; 17: 19-26
    CrossrefPubMedGoogle Scholar
  • 41 Vigon I, Dreyfus F, Melle J. et al Expression of the c-mpl proto-oncogene in human hematologic malignancies. Blood 1993; 82: 877-83
    PubMedGoogle Scholar
  • 42 Fisher MJ, Prchal JF, Prchal JT, D'Andrea AD. Antierythropoietin (EPO) receptor monoclonal antibodies distinguish EPOdependent and EPO-independent erythroid progenitors in polycythemia vera. Blood 1994; 84: 1982-91
    PubMedGoogle Scholar
  • 43 Casadevall B, Vainchenker W, Lacombe C. Erythroid progenitors in polycythemia vera: Demonstration of their hypersensitivity to erythropoietin using serum free cultures. Blood 1982; 59: 447-51
    PubMedGoogle Scholar
  • 44 Dai CH, Krantz SB, Green WF, Gilbert HS. Polycythaemia vera. III. Burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression. Br J Haematol 1994; 86: 12-21
    CrossrefPubMedGoogle Scholar
  • 45 de Wolf JT, Hendriks DW, Esselink MT, Halie MR, Vellenga E. The effects of IL-1 and IL-4 on the Epo-independent erythroid progenitor in polycythaemia vera. Br J Haematol 1994; 88: 242-6
    CrossrefPubMedGoogle Scholar
  • 46 Correa PN, Eskinazi D, Axelrad AA. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. Blood 1994; 83: 99-112
    PubMedGoogle Scholar
  • 47 Siitonen T, Zheng A, Savolainen ER, Koistinen P. The effect of interleukin-4 with or without mast cell growth factor on peripheral blood granulocyte-macrophage colony-forming cells in healthy controls and in myeloproliferative disorders. Ann Hematol 1995; 70: 203-7
    CrossrefPubMedGoogle Scholar
  • 48 Siitonen T, Savolainen ER, Koistinen P. Expression of the c-kit proto-oncogene in myeloproliferative disorders and myelodysplastic syndromes. Leukemia 1994; 8: 631-7
    PubMedGoogle Scholar
  • 49 Sokol L, Prchal JF, D'Andrea A, Rado TA, Prchal JT. Mutation in the negative regulatory element of the erythropoietin receptor gene in a case of sporadic primary polycythemia. Exp Hematol 1994; 22: 447-53
    PubMedGoogle Scholar
  • 50 Sokol L, Luhovy M, Guan Y, Prchal JF, Semenza GL, Prchal JT. Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. Blood 1995; 86: 15-22
    PubMedGoogle Scholar
  • 51 Prchal JT, Prchal JF. Evolving understanding of the cellular defect in polycythemia vera: implications for its clinical diagnosis and molecular pathophysiology. Blood 1994; 83: 1-4
    PubMedGoogle Scholar
  • 52 Hess G, Rose P, Gamm H, Papadileris S, Huber C, Seliger B. Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera. Br J Haematol 1994; 88: 794-802
    CrossrefPubMedGoogle Scholar
  • 53 Florensa L, Besses C, Woessner S. et al Endogenous megakaryocyte and erythroid colony formation from blood in essential thrombocythaemia. Leukemia 1995; 9: 271-3
    PubMedGoogle Scholar
  • 54 Juvonen E, Ikkala E, Oksanen K, Ruutu T. Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications. Br J Haematol 1993; 83: 192-7
    CrossrefPubMedGoogle Scholar
  • 55 Dai CH, Krantz SB, Dessypris EN, Means RT, Horn ST, Gilbert HS. Polycythemia vera II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood 1992; 80: 891-899
    PubMedGoogle Scholar
  • 56 Kobayashi S, Teramura M, Hoshino S, Motoji T, Oshimi K, Mizoguchi H. Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3. Br J Haematol 1993; 83: 539-44
    CrossrefPubMedGoogle Scholar
  • 57 Zauli G, Bagnara GP, Catani L, Vitale L, Gugliotta L, Rizzoli C. Impaired regulation of megakaryocytopoiesis in essential thrombocythemia. Ann NY Acad Sci 1991; 628: 190-1
    CrossrefPubMedGoogle Scholar
  • 58 Li Y, Hetet G, Maurer AM, Chait Y, Dhermy D, Briere J. Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF. Br J Haematol 1994; 87: 471-6
    CrossrefPubMedGoogle Scholar
  • 59 Li Y, Hetet G, Kiladjian J-J, Gardin C, Grandchamp B, Briere J. Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders. Br J Hematol 1996; 92: 60-6
    CrossrefPubMedGoogle Scholar
  • 60 Holme S, Simmonds M, Ballek R, Murphy S. Comparative measurements of platelet size by Coulter counter, microscopy of blood smears, and light transmission studies. J Lab Clin Med 1981; 97: 610-22
    PubMedGoogle Scholar
  • 61 Small BM, Bettigole RE. Diagnosis of myeloproliferative disease by analysis of the platelet volume distribution. Am J Clin Pathol 1981; 76: 685-91
    CrossrefPubMedGoogle Scholar
  • 62 Wehmeier A. Differentialdiagnostische Parameter der Thrombozytose. Lab med 1991; 15: 546-50
    PubMedGoogle Scholar
  • 63 Holme S, Murphy S. Coulter counter and light transmission studies of platelets exposed to low temperature, ADP, EDTA, and storage at 22° C. J Lab Clin Med 1980; 96: 480-93
    PubMedGoogle Scholar
  • 64 Wehmeier A, Schneider W. Platelet volume as a diagnostic tool: the influence of anticoagulation and storage conditions on platelet impedance volume. Klin Wschr 1989; 67: 980-4
    CrossrefPubMedGoogle Scholar
  • 65 Maldonado JE, Pintado T, Pierre RV. Dysplastic platelets and circulating megakaryocytes in chronic myeloproliferative disorders: I. The platelets: Ultrastructure and Peroxydase reaction. Blood 1974; 43: 797-809
    PubMedGoogle Scholar
  • 66 Holme S, Murphy S. Studies of the platelet density abnormality in myeloproliferative disease. J Lab Clin Med 1984; 103: 373-83
    PubMedGoogle Scholar
  • 67 Caranobe C, Sie P, Laurent G, Pris J Boneu B. Platelets in myeloproliferative disorders: II. Serotonin uptake and storage: correlation with mepacrine labelled dense bodies and with platelet density. Scand J Haematol 1980; 25: 289-95
    PubMedGoogle Scholar
  • 68 Leoncini G, Balestrero F, Marcesca M, Armani U, Piana A. Platelet lysosomal enzymes are normal in myeloproliferative disorders. Acta Haemat 1984; 72: 190-4
    CrossrefPubMedGoogle Scholar
  • 69 Pareti F. l, Gugliotta L, Mannucci L, Guarini A, Mannucci PM. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disease. Thromb Haemost 1982; 47: 84-9
    Article in Thieme ConnectPubMedGoogle Scholar
  • 70 Wehmeier A, Scharf RE, Fricke S, Schneider W. Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease. Haemostasis 1989; 19: 251-9
    PubMedGoogle Scholar
  • 71 Grossi A, Vannucchi AM, Rafanelli D, Filimberti E, Ferrini PR. Beta-thromboglobulin content in megakaryocytes of patients with myeloproliferative diseases. Thromb Res 1986; 43: 367-74
    CrossrefPubMedGoogle Scholar
  • 72 Boughton BJ, Allington MJ, King A. Platelet and plasma ß-thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis. Br J Haematol 1978; 40: 125-32
    CrossrefPubMedGoogle Scholar
  • 73 Cortelazzo S, Viero P, Barbui T. Platelet activation in myeloproliferative disorders. Thromb Haemost 1981; 45: 211-3
    Article in Thieme ConnectPubMedGoogle Scholar
  • 74 Castro-Malaspina H, Rabellino EM, Yen A, Nachman RL, Moore MAS. Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood 1981; 57: 781-7
    CrossrefPubMedGoogle Scholar
  • 75 Gersuk GM, Carmel R, Pettengale PK. Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders. Blood 1989; 74: 2330-4
    PubMedGoogle Scholar
  • 76 Han ZC, Bellucci S, Tenza D, Caen JP. Negative regulation of human megakaryocytopoiesis by human platelet factor 4 and beta-thromboglobulin: comparative analysis in bone marrow cultures from normal individuals and patients with essential thrombocythemia and immune thrombocytopenic purpura. Br J Haematol 1990; 74: 395-401
    CrossrefPubMedGoogle Scholar
  • 77 Zahavi J. Acquired »storage pool disease« of platelets. Thromb Haemost 1976; 35: 501-7
    Article in Thieme ConnectPubMedGoogle Scholar
  • 78 Nishimura J, Okamoto S, Ibayashi H. Abnormalities of platelet adenine nucleotides in patients with myeloproliferative disorders. Thromb Haemost 1979; 41: 787-95
    Article in Thieme ConnectPubMedGoogle Scholar
  • 79 Rendu F, Lebret M, Nurden A, Caen JP. Detection of an acquired storage pool deficiency in three patients with a myeloproliferative disorder. Thromb Haemost 1979; 42: 794-6
    Article in Thieme ConnectPubMedGoogle Scholar
  • 80 Lages B, Holmsen H, Weiss HJ, Dangelmaier C. Thrombin and ionophore A 23187-induced dense granule secretion in storage pool deficient platelets. Evidence for impaired nucleotide storage as the primary dense granule defect. Blood 1983; 61: 154-62
    PubMedGoogle Scholar
  • 81 Malpass TW, Savage B, Hanson SR, Slichter SJ, Harker LA. Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders. J Lab Clin Med 1984; 103: 894-904
    PubMedGoogle Scholar
  • 82 Cortelazzo S, Viero P, Buczko W, Barbui T, de Gaetano G. Platelet 5-hydroxytryptamine transport and storage in myeloproliferative disorders. Scand J Haematol 1985; 34: 146-51
    PubMedGoogle Scholar
  • 83 Didisheim P, Bunting D. Abnormal platelet function in myelofibrosis. Am J Clin Pathol 1966; 45: 566-73
    CrossrefPubMedGoogle Scholar
  • 84 Zucker S, Mielke CH. Classification of thrombocytosis based on platelet function tests. J Lab Clin Med 1972; 80: 385-94
    PubMedGoogle Scholar
  • 85 Barbui T, Cortelazzo S, Viero P, Bassan R, Dini E, Semeraro N. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: Relationship to platelet number and function. Eur J Cancer Clin Oncol 1983; 19: 1593-9
    CrossrefPubMedGoogle Scholar
  • 86 Berger S, Aledort LM, Gilbert HS, Hanson JP, Wasserman LR. Abnormalities of platelet function in patients with polycythemia vera. Cancer Res 1973; 33: 2683-7
    PubMedGoogle Scholar
  • 87 Boughton BJ. Chronic myeloproliferative disorders: Improved platelet aggregation following venesection. Br J Haematol 1978; 39: 589-98
    CrossrefPubMedGoogle Scholar
  • 88 Wehmeier A, Scharf RE, Fricke S, Schneider W. A prospective study of hemostatic parameters in relation to the clinical course of myeloproliferative disorders. Eur J Hematol 1990; 45: 191-7
    PubMedGoogle Scholar
  • 89 Barbui T, Bassan R, Viero P, Cortelazzo S, Dini E. Platelet function after busulphan in chronic myeloproliferative disorders. Haematologica 1983; 68: 469-77
    PubMedGoogle Scholar
  • 90 Baker R. l, Manoharan A. Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time. Eur J Haematol 1988; 40: 267-72
    PubMedGoogle Scholar
  • 91 Neemeh JA, Bowie EJW, Thompson JH, Didisheim P, Owen CA. Quantitation of platelet aggregation in myeloproliferative disorders. Am J Clin Pathol 1972; 57: 336-47
    CrossrefPubMedGoogle Scholar
  • 92 Kaywin P, McDonough M, Insel PA, Shattil S. Platelet function in essential thrombocythemia: decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors. N Engl J Med 1978; 299: 505-9
    CrossrefPubMedGoogle Scholar
  • 93 Swart SS, Pearson D, Wood JK, Barnett DB. Functional significance of the alpha-2- adrenoceptor: studies in patients with myeloproliferative disorders. Thromb Res 1984; 33: 531-41
    CrossrefPubMedGoogle Scholar
  • 94 Ushikubi F, Okuma M, Ishibashi T, Narumiya S, Uchino H. Deficient elevation of the cytoplasmic calcium ion concentration by epinephrine in epinephrine-insensitive platelets of patients with myeloproliferative disorders. Am J Hematol 1990; 33: 96-100
    CrossrefPubMedGoogle Scholar
  • 95 Wu KY. Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Int Med 1978; 88: 7-11
    CrossrefPubMedGoogle Scholar
  • 96 Waddell CC, Brown JA, Repinecz YA. Abnormal platelet function in myeloproliferative disorders. Arch Pathol Lab Med 1981; 105: 432-5
    PubMedGoogle Scholar
  • 97 Barbui T, Battista R, Dini E. Spontaneous platelet aggregation in myeloproliferative disorders. Acta haemat 1973; 50: 25-9
    CrossrefPubMedGoogle Scholar
  • 98 Balduini CL, Bertolini G, Noris P, Piletta GC. Platelet aggregation in plateletrich plasma and whole blood in 120 patients with myeloproliferative disorders. Am J Clin Pathol 1991; 95: 82-6
    CrossrefPubMedGoogle Scholar
  • 99 Keenan JP, Wharton J, Sheperd ANJ, Bellingham AJ. Defective platelet lipid peroxydation in myeloproliferative disorders: a possible defect of prostaglandin synthesis. Br J Haematol 1977; 35: 275-83
    CrossrefPubMedGoogle Scholar
  • 100 Jubelirer SJ, Russell F, Vaillancourt R, Deykin D. Platelet arachidonic acid metabolism and platelet function in ten patients with chronic myelogenous leukemia. Blood 1980; 56: 728-31
    PubMedGoogle Scholar
  • 101 Okuma M, Uchino H. Altered arachidonate metabolism by platelets in patients with myeloproliferative disorders. Blood 1979; 54: 1258-71
    PubMedGoogle Scholar
  • 102 Schafer A. l. Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. N Engl J Med 1982; 306: 381-6
    CrossrefPubMedGoogle Scholar
  • 103 Mehta P, Mehta J, Ross M, Ostrowski N, Player D. Decreased platelet aggregation but increased thromboxane A2 generation in polycythemia vera. Arch Int Med 1985; 145: 1225-7
    CrossrefPubMedGoogle Scholar
  • 104 Zahavi J, Zahavi M, Firsteter E, Frish B, Turleanu R, Rachmani P. An abnormal pattern of multiple platelet function abnormalities and increased thromboxane generation in patients with primary thrombocytosis and thrombotic complications. Eur J Haematol 1991; 47: 326-32
    CrossrefPubMedGoogle Scholar
  • 105 Mayordomo O, Carcamo C, Vecino AM, Navarro JL, Cesar JM. Arachidonic acid metabolism in platelets of patients with essential thrombocythaemia. Thromb Res 1995; 78: 315-21
    CrossrefPubMedGoogle Scholar
  • 106 Smith IL, Martin TJ. Platelet thromboxane synthesis and release reactions in myeloproliferative disorders. Haemostasis 1982; 11: 119-27
    PubMedGoogle Scholar
  • 107 van Genderen PJ, Michiels JJ, Zijlstra FJ. Lipoxygenase deficiency in primary thrombocythemia is not a true deficiency. Thromb Haemost 1994; 71: 803-4
    Article in Thieme ConnectPubMedGoogle Scholar
  • 108 Stenke L, Edenius C, Samuelsson J, Lindgren JA. Deficient lipoxin synthesis: a novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia. Blood 1991; 78: 2989-95
    PubMedGoogle Scholar
  • 109 Cooper B, Schafer AI, Puchalsky D, Handin RI. Platelet resistance to prostaglandin D2 in patients with myeloproliferative disorders. Blood 1978; 52: 618-26
    PubMedGoogle Scholar
  • 110 Cooper B, Ahern D. Characterization of the platelet prostaglandin D2 receptor. J Clin Invest 1979; 64: 586-90
    CrossrefPubMedGoogle Scholar
  • 111 Cortelazzo S, Galli M, Castagna D, Viero P, Gaetano Gd, Barbui T. Increased response to arachidonic acid and U-46619 and resistance to inhibitory prostaglandins in patients with myeloproliferative disorders. Thromb Haemost 1988; 59: 73-6
    Article in Thieme ConnectPubMedGoogle Scholar
  • 112 Bolin RB, Okumura T, Jamieson GA. Changes in distribution of platelet membrane glycoproteins in patients with myeloproliferative disorders. Am J Hematol 1977; 3: 63-71
    CrossrefPubMedGoogle Scholar
  • 113 Eche N, Sie P, Caranobe C, Nouvel C, Pris J, Boneu B. Platelets in myeloproliferative disorders. III: Glycoprotein profile in relation to platelet function and platelet density. Scand J Hematol 1981; 26: 123-9
    PubMedGoogle Scholar
  • 114 Clezardin P, McGregor JL, Dechavanne M, Clemetson KL. Platelet membrane glycoprotein abnormalities in patients with myeloproliferative disorders and secondary thrombocytosis. Br J Haematol 1985; 60: 331-44
    CrossrefPubMedGoogle Scholar
  • 115 Mazzucato M, Marco Ld, Angelis Vd, Roia Dd, Bizzaro N, Casonato A. Platelet membrane abnormalities in myeloproliferative disorders: decrease in glycoproteins lb and IIb/IIIa complex is associated with deficient receptor function. Br J Haematol 1989; 73: 369-74
    CrossrefPubMedGoogle Scholar
  • 116 Mistry R, Cahill M, Chapman C, Wood JK, Barnett DB. 125J-fibrinogen binding to platelets in myeloproliferative disease. Thromb Haemost 1991; 66: 329-33
    Article in Thieme ConnectPubMedGoogle Scholar
  • 117 Landolfi R, Cristofaro Rd, Castagnola M. et al Increased platelet-fibrinogen affinity in patients with myeloproliferative disorders. Blood 1988; 71: 978-82
    PubMedGoogle Scholar
  • 118 Thibert V, Bellucci S, Edelman L, Tandon NN, Legrand C. Quantitation of platelet glycoprotein IV (CD36) in healthy subjects and in patients with essential thrombocythemia using an immunocapture assay. Thromb Haemost 1992; 68: 600-5
    Article in Thieme ConnectPubMedGoogle Scholar
  • 119 Legrand C, Bellucci S, Disdier M, Edelman L, Tobelem G. Platelet thrombospondin and glycoprotein IV abnormalities in patients with essential thrombocythemia: effect of alpha-interferon treatment. Am J Hematol 1991; 38: 307-13
    CrossrefPubMedGoogle Scholar
  • 120 Handa M, Watanabe K, Kawai Y. et al Platelet unresponsiveness to collagen: involvement of glycoprotein Ia-IIa (alpha 2 beta 1 integrin) deficiency associated with a myeloproliferative disorder. Thromb Haemost 1995; 73: 521-8
    Article in Thieme ConnectPubMedGoogle Scholar
  • 121 Eigenthaler M, Ullrich H, Geiger J. et al Defective nitrovasodilator-stimulated protein phosphorylation and calcium regulation in cGMP-dependent protein kinasedeficient human platelets of chronic myelocytic leukemia. J Biol Chem 1993; 268: 13526-31
    PubMedGoogle Scholar
  • 122 Chien S, Gallik S.. Rheology in normal individuals and polycythemia vera. In: Polycythemia vera and the myeloproliferative disorders. Wasserman LR, Berk PD, Berlin NI. (ed) Philadelphia: W B Saunders Company; 1995: 114-29
    Google Scholar
  • 123 Cancelas JA, Garcia-Avello A, GarciaFrade LJ. High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis. Thromb Res 1994; 75: 513-20
    CrossrefPubMedGoogle Scholar
  • 124 Bazzan M, Tamponi G, Gallo E. et al Fibrinolytic imbalance in essential thrombocythemia: role of platelets. Haemostasis 1993; 23: 38-44
    PubMedGoogle Scholar
  • 125 Bellucci S, Ignatova E, Jaillet N, Boffa MC. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF. Thromb Haemost 1993; 70: 736-42
    Article in Thieme ConnectPubMedGoogle Scholar
  • 126 Leupin L, Beck A, Furlan M, Bucher U. Hämostasestörung mit verminderter Aktivität des von Willebrand-Faktors bei myeloproliferativen Syndromen. Schweiz med Wschr 1983; 113: 713-6
    PubMedGoogle Scholar
  • 127 Budde U, Dent JA, Berkowitz SD, Ruggeri ZM, Zimmerman TS. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood 1986; 69: 1213-7
    PubMedGoogle Scholar
  • 128 Castaman G, Lattuada A, Ruggeri M, Tosetto A, Mannucci PM, Rodeghiero F. Platelet von Willebrand factor abnormalities in myeloproliferative syndromes. Am J Hematol 1995; 49: 289-93
    CrossrefPubMedGoogle Scholar
  • 129 Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993; 82: 1749-57
    PubMedGoogle Scholar
  • 130 van Genderen PJ, Michiels JJ, van der Poelvan de Luytgaarde SC, van Vliet HH. Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. Ann Hematol 1994; 69: 81-4
    CrossrefPubMedGoogle Scholar
  • 131 Wong PMC, Chung SW, Dunbar CE, Bodine DM, Ruscetti S, Nienhuis AW. Retrovirus-mediated transfer and expression of the interleukin-3 gene in mouse hematopoietic cells result in a myeloproliferative disorder. Molec Cell Biol 1989; 9: 798-808
    CrossrefPubMedGoogle Scholar
  • 132 Chang JM, Metcalf D, Lang RA, Gonda TJ, Johnson GR. Nonneoplastic hematopoietic myeloproliferative syndrome induced by dysregulated multi-CSF (IL-3) expression. Blood 1989; 73: 1487-97
    PubMedGoogle Scholar
  • 133 Courtois G, Benit L, Mikaeloff Y. et al Constitutive activation of a variant of the envmpl oncogene product by disulfidelinked homodimerization. J Virol 1995; 69: 2794-800
    PubMedGoogle Scholar
  • 134 Yan XQ, Brady G, Iscove NN. Overexpression of PDGF-B in murine hematopoietic cells induces a lethal myeloproliferative syndrome in vivo. Oncogene 1994; 9: 163-73
    PubMedGoogle Scholar
  • 135 LeBousse-Kerdilès M-C, Souyri M, Smadja-Joffe F, Praloran V, Jasmin C, Ziltener HJ. Enhanced hematopoietic growth factor production in an experimental myeloproliferative syndrome. Blood 1992; 79: 3179-87
    PubMedGoogle Scholar
  • 136 Longmore GD, Watowich SS, Hilton DJ, Lodish HF. The erythropoietin receptor: its role in hematopoiesis and myeloproliferative diseases. J Cell Biol 1993; 123: 1305-8
    CrossrefPubMedGoogle Scholar
  • 137 Dai CH, Krantz SB, Koury ST, Kollar K. Polycythaemia vera. IV. Specific binding of stem cell factor to normal and polycythaemia vera highly purified erythroid progenitor cells. Br J Haematol 1994; 88: 497-505
    CrossrefPubMedGoogle Scholar
  • 138 Columbyova L, Loda M, Scadden DT. Thrombopoietin receptor expression in human cancer cell lines and primary tissues. Cancer Res 1995; 55: 3509-12
    PubMedGoogle Scholar
  • 139 Mirza AM, Correa PN, Axelrad AA. Increased basal and induced tyrosine phosphorylation of the insulin-like growth factor I receptor beta subunit in circulating mononuclear cells of patients with polycythemia vera. Blood 1995; 86: 877-82
    PubMedGoogle Scholar
  • 140 Buijs A, Sherr S, van Baal S. et al Translocation (12; 22) (p13; q11) in myeloproliferative disorders results in fusion of the ETSlike TEL gene on 12p13 to the MN1 gene on22q11. Oncogene 1995; 10: 1511-9
    PubMedGoogle Scholar
  • 141 Behringer D, Schaefer HE, Kunzmann R, Mertelsmann R, Dolken G. Translocation t(8; 13) in a patient with T cell lymphoma and features of a myeloproliferative syndrome. Leukemia 1995; 9: 988-92
    PubMedGoogle Scholar
  • 142 Kempski H, MacDonald D, Michalski AJ. et al Localization of the 8; 13 translocation breakpoint associated with myeloproliferative disease to a 1.5 Mbp region of chromosome 13. Genes Chromosom Cancer 1995; 12: 283-7
    CrossrefPubMedGoogle Scholar
  • 143 Leslie J, Barker T, Glancy M, Jennings B, Pearson J. t(8; 13) (p11; q12) translocation in a myeloproliferative disorder associated with a T-cell non-Hodgkin lymphoma. Br J Haematol 1994; 86: 876-8
    CrossrefPubMedGoogle Scholar
  • 144 Schlemper RJ, van der Maas AP, Eikenboom JC. Familial essential thrombocythemia: clinical characteristics of 11 cases in one family. Ann Hematol 1994; 68: 153-8
    CrossrefPubMedGoogle Scholar
  • 145 Zauber NP, Vlad LD. Myeloproliferative disorders in two New Jersey families. N J Med 1995; 92: 530-2
    PubMedGoogle Scholar
  • 146 Nakamura H, Hayashibara T, Kawachi T. et al Chromosome 11 rearrangement at band Hq21 in a patient with essential thrombocythemia. Cancer Genet Cytogenet 1992; 58: 105-7
    CrossrefPubMedGoogle Scholar
  • 147 Gaidano G, Guerrasio A, Serra A. et al Mutations in the P53 and RAS family genes are associated with tumor progression of BCR/ABL negative chronic myeloproliferative disorders. Leukemia 1993; 7: 946-53
    PubMedGoogle Scholar
  • 148 Gaidano G, Guerrasio A, Serra A, Rege-Cambrin G, Saglio G. Molecular mechanisms of tumor progression in chronic myeloproliferative disorders. Leukemia 1994; 8: S27-9
    PubMedGoogle Scholar
  • 149 Marmont AM, Sessarego M. Chronic clonal myeloproliferative disease associated with a t(5; 21) translocation. Complete but transient hematologic and cytogenetic remission induced by interferon-alpha. Leukemia 1995; 9: 977-80
    PubMedGoogle Scholar
  • 150 Negrini M, Cuneo A, Nakamura T. et al A novel t(9; 11)(p22; q23) with ALL-1 gene rearrangement associated with progression of a myeloproliferative disorder to acute myeloid leukemia. Cancer Genet Cytogenet 1995; 83: 65-70
    CrossrefPubMedGoogle Scholar
  • 151 Murphy S.. Megakaryocytes, platelets, and coagulation in the myeloproliferative diorders. In: Polycythemia vera and the myeloproliferative disorders. . Wasserman LR, Berk PD, Berlin NI. (ed). Philadelphia: W B Saunders Company; 1995: 102-13
    Google Scholar
  • 152 Barbui T, Buelli M, Cortelazzo S, Viero P, deGaetano G. Aspirin and risk of bleeding in patients with thrombocythemia. Am J Med 1987; 83: 265-8
    CrossrefPubMedGoogle Scholar
  • 153 van Genderen PJ, Michiels JJ, van Strik R, Lindemans J, van Vliet HH. Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. Thromb Haemost 1995; 73: 210-4
    Article in Thieme ConnectPubMedGoogle Scholar
  • 154 Viero P, Cortelazzo S, Bassan R, Barbui T. Effect of aspirin on platelet 5-hydroxytryptamine and beta-thromboglobulin plasma levels in patients with myeloproliferative disease. Thromb Haemost 1982; 48: 125-6
    Article in Thieme ConnectPubMedGoogle Scholar
  • 155 Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 1986; 23: 172-6
    PubMedGoogle Scholar
  • 156 Hoagland HC, Silverstein MN. Primary thrombocythemia in the young patient. Mayo Clin Proc 1978; 53: 578-80
    PubMedGoogle Scholar
  • 157 Kessler CM, Klein HG, Havlik RJ. Uncontrolled thrombocytosis in myeloproliferative disorders. Br J Haematol 1982; 50: 157-67
    CrossrefPubMedGoogle Scholar
  • 158 Barbui T, Cortelazzo S, Viero P, Bassan R, Dini E, Semeraro N. Thrombohemorrhagic' complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function. Eur J Cancer Clin Oncol 1983; 19: 1593-99
    CrossrefPubMedGoogle Scholar
  • 159 Schafer A. l. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64: 1-12
    PubMedGoogle Scholar
  • 160 Cortelazzo S, Finazzi G, Ruggeri M. et al Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332: 1132-6
    CrossrefPubMedGoogle Scholar
  • 161 Landaw SA. Acute leukemia in polycythemia vera. In: Polycythemia vera and the myeloproliferative disorders. Wasserman LR, Berk PD, Berlin NI. (ed). Philadelphia: WB Saunders Company; 1995: 154-65
    Google Scholar
  • 162 Berk PD, Goldberg JD, Silverstein MN. et al Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981; 304: 441-7
    CrossrefPubMedGoogle Scholar
  • 163 Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol 1994; 52: 134-9
    PubMedGoogle Scholar
  • 164 Boivin P. Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea. Nouv Rev Fr Hematol 1993; 35: 491-8
    PubMedGoogle Scholar
  • 165 Spadea A, Petti HC, Spiriti HAA. et al Pipobroman in polycythemia vera patients: a retrospective analysis. Blood 1994; 84 (Suppl. 01) 58a
    PubMedGoogle Scholar
  • 166 Hasselbalch HC. Idiopathic myelofibrosis an update with particular reference to clinical aspects and prognosis. Int J Clin Lab Res 1993; 23: 124-38
    CrossrefPubMedGoogle Scholar
  • 167 Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous hematocrit in primary proliferative polycythemia. Lancet 1978; ii: 1219-22
    PubMedGoogle Scholar
  • 168 Ferrant A. What clinical and laboratory data are indicative of polycythemia and when are blood volume studies needed?. Nouv Rev Fr Hematol 1994; 36: 151-4
    PubMedGoogle Scholar
  • 169 Sacchi S, Leoni P, Liberati M. et al A prospective comparison between treatment with phlebotomy alone and with interferonalpha in patients with polycythemia vera. Ann Hematol 1994; 68: 247-50
    CrossrefPubMedGoogle Scholar
  • 170 Bilgrami S, Greenberg BR. Polycythemia rubra vera. Semin Oncol 1995; 22: 307-26
    PubMedGoogle Scholar
  • 171 Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990; 8: 556-62
    CrossrefPubMedGoogle Scholar
  • 172 Randi ML, Fabris F, Rossi C, Tison T, Barbone E, Girolami A. Sex and age as prognostic factors in essential thrombocythemia. Haematologica 1992; 77: 402-4
    PubMedGoogle Scholar
  • 173 Randi ML, Fabris F, Girolami A. Thrombocytosis in young people: evaluation of 57 cases diagnosed before the age of 40. Blut 1990; 60: 233-7
    CrossrefPubMedGoogle Scholar
  • 174 Millard FE, Hunter CS, Anderson M. et al Clinical manifestations of essential thrombocythemia in young adults. Am J Hematol 1990; 33: 27-31
    CrossrefPubMedGoogle Scholar
  • 175 Frezzato M, Ruggeri M, Castaman G, Rodeghiero F. Polycythemia vera and essential thrombocythemia in young patients. Haematologica 1993; 78 6 Supp (Suppl. 12) 11-7
    PubMedGoogle Scholar
  • 176 Mclntyre KJ, Hoagland HC, Silverstein MN, Petitt RM. Essential thrombocythemia in young adults. Mayo Clin Proc 1991; 66: 149-54
    CrossrefPubMedGoogle Scholar
  • 177 Mitus AJ, Barbui T, Shulman LN. et al Hemostatic complications in young patients with essential thrombocythemia. Am J Med 1990; 88: 371-5
    CrossrefPubMedGoogle Scholar
  • 178 Mazur EM, Rosmarin AG, Sohl PA, Newton JL, Narendran A. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 1992; 79: 1931-7
    PubMedGoogle Scholar
  • 179 Spencer CM, Brogden RN. Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. Drugs 1994; 47: 809-22
    CrossrefPubMedGoogle Scholar
  • 180 Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992; 92: 69-76
    CrossrefPubMedGoogle Scholar
  • 181 Silverstein MN. Anagrelide in myeloproliferative diseases. In: Polycythemia vera and the myeloproliferative disorders. Wasserman LR, Berk PD, Berlin NI. (ed). Philadelphia: WB Saunders Company; 1995: 329-36
    Google Scholar
  • 182 Talpaz M. Use of interferon in the treatment of chronic myelogenous leukemia. Semin Oncol 1994; 6 (Suppl. 14) 3-7
    PubMedGoogle Scholar
  • 183 Gugliotta L, Bagnara GP, Catani L. et al In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia. Br J Haematol 1989; 71: 177-81
    CrossrefPubMedGoogle Scholar
  • 184 Chott A, Gisslinger H, Thiele J. et al Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. Br J Haematol 1990; 74: 10-6
    CrossrefPubMedGoogle Scholar
  • 185 Franco V, Florena AM, Aragona F, Campesi G. Morphometric study of the bone marrow in polycythemia vera following interferon-alpha therapy. Pathol Res Pract 1993; 189: 52-7
    CrossrefPubMedGoogle Scholar
  • 186 Messora C, Bensi L, Vecchi A. et al Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol 1994; 86: 402-4
    CrossrefPubMedGoogle Scholar
  • 187 Hino M, Futami E, Okuno S, Miki T, Nishizawa Y, Morii H. Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera. Ann Hematol 1993; 66: 161-2
    CrossrefPubMedGoogle Scholar
  • 188 Zeitschriften Cunningham DD, Pulliam L, Vaughan PJ. Protease nexin-1 and thrombin: Injury related processes in the brain. Thromb Haemost 1993; 70: 168-71
    Article in Thieme ConnectPubMedGoogle Scholar
  • 189 Hawiger J. (ed). Methods in Enzymology. Platelets: Receptors, Adhesion, Secretion. Part A, Vol. 169. San Diego: Academic Press; 1989
    Google Scholar
  • 190 Schrör K, Hohlfeld T. Koagulation, Thrombolyse und Fibrinolyse bei myokardialer Ischämie. In: Pathophysiologie und rationale Pharmakotherapie der Myokardischämie. . Heusch G. (Hrsg). Darmstadt: Steinkopff; 1990: 89-117
    Google Scholar